OncoMatch/Clinical Trials/NCT07063693
ABY-029 Glioma Trial
Is NCT07063693 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies ABY-029 for intracranial tumor.
Treatment: ABY-029 — The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Grade: high
Prior therapy
Cannot have received: EGFR tyrosine kinase inhibitor
Participants on any experimental or approved anti-EGFR targeted therapies
Lab requirements
Kidney function
kidney function tests levels greater than 2.5 times the normal limit excluded
Liver function
liver function tests levels greater than 2.5 times the normal limit excluded
Elevated kidney or liver function tests (levels greater than 2.5 times the normal limit) from laboratory tests conducted as part of standard-of-care screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify